Ranbaxy gets USFDA nod for amlodipine besylate

New Delhi, July 10 (UNI) Ranbaxy Laboratories Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market amlodipine besylate tablets in multiple strengths.

The drug which is the the generic equivalent of Pfizer's Norvasc tablets are used to treat hypertension, it said in a statement.

The annual sales for Norvasc were 2.79 billion dollars, it added.

''We are pleased to receive the final FDA approval for Amlodipine Besylate Tablets, which represents Ranbaxy's 115th ANDA approval to date. This product will further expand our product portfolio of affordable generic alternatives and will be launched in August to all classes of trade,'' Ranbaxy Pharmaceuticals Inc Vice President (Sales and Marketing) Jim Meehan said.

Ranbaxy Pharmaceuticals Inc based in Florida, US, is a wholly-owned subsidiary of the company and is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

UNI